A Phase 2 interventional study of Placebo matched to atacicept and Atacicept: with loading dose in Rheumatoid Arthritis, sponsored by EMD Serono. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-17.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 121 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.
Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 200th largest by enrollment of the 771 interventional ones that give a count, is one of 51 that started in 2007, is one of 215 in phase 2, and was the 202nd registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:
Tufts Medical Center · Sites in United States
Ages 18+
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Bristol-Myers Squibb · Sites in United States, Belgium, Brazil and 8 more countries
Ages 18–65
Fate Therapeutics · Sites in United States
Ages 18–70
PTC Therapeutics · Sites in United States, Georgia, Mauritius and 1 more country
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
975 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 161 · Phase 2 252 · Phase 3 172 · Phase 4 61
First in 1991; this study’s year is marked. 51 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 311 is above the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 120 across the 771 interventional studies, 200 across the 199 observational. Of the 803 that completed or were terminated, 417 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
629 of 975 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 7 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
37 of the studies in Arthritis, Rheumatoid with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06201416Sonoma Biotherapeutics, Inc.Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis | 2026-11 |
| NCT05961592Rise Therapeutics LLCR-2487 in Patients With Rheumatoid Arthritis | 2026-11-30 |
| NCT03409718Zimmer BiometDatabase Retrieval for the Comprehensive Shoulder | 2026-12 |
| NCT01480440Zimmer BiometOutcomes Study of the Trabecular Metal (TM) Reverse Shoulder System | 2026-12 |
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
Add all 37 to your calendar (.ics) → With an account.
Among the 975 studies in Arthritis, Rheumatoid with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of atacicept compared to placebo in the treatment of signs and symptoms in a subject population with active rheumatoid arthritis (RA), inadequate response to methotrexate (MTX) and no previous exposure to anti-tumor necrosis factor alpha (anti-TNFalpha) therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Atacicept: with loading dose
Drug: Atacicept
Biological: Adalimumab
Drug: Placebo matched to atacicept
Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
Drug page: TACI receptor-IgG Fc fragment fusion proteinStudies of TACI receptor-IgG Fc fragment fusion proteinTACI receptor-IgG Fc fragment fusion protein pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
Atacicept will be administered subcutaneously at a dose of 150 mg once a week for 25 weeks.
Adalimumab (Humira®) will be administered subcutaneously at a dose of 40 mg every other week for 25 weeks.
Also known as: Humira®
Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26
ACR20-CRP response is defined as greater than or equal to (\>=) 20 percent (%) improvement from Baseline in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement from Baseline in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).
Time frame: Week 26
Percentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 26
ACR50-CRP response is defined as \>=50% improvement from Baseline in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=50% improvement from Baseline in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).
Time frame: Week 26
Percentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 26
ACR70-CRP response is defined as \>=70% improvement from Baseline in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=70% improvement from Baseline in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).
Time frame: Week 26
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 26
The EULAR response criteria evaluate change in DAS28 scores represented as "good response", "moderate response", or "no response" considering both the current DAS28 score and the observed improvement from baseline. Participants were considered to have "good" or "moderate" EULAR response if at the time of assessment, their DAS28 score was less than or equal to (\<=) 5.1 and the improvement from baseline in their DAS28 score was greater than (\>) 0.6; or if at the time of assessment, their DAS28 score was \>5.1 and improvement from baseline in their DAS28 score was \>1.2.
Time frame: Week 26
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.
Time frame: From the first dose of study drug up to 30 days after the last dose of study drug, assessed up to Week 38
| Milestone | Placebo | Atacicept 150 mg With Loading Dose | Atacicept 150 mg Without Loading Dose | Adalimumab |
|---|---|---|---|---|
| Started | 76 | 78 | 78 | 79 |
| Completed | 69 | 73 | 70 | 75 |
| Not completed | 7 | 5 | 8 | 4 |
| Withdrew: Adverse event | 0 | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 2 | 1 | 3 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Other | 5 | 1 | 5 | 0 |
ACR20-CRP response is defined as greater than or equal to (\>=) 20 percent (%) improvement from Baseline in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement from Baseline in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).
| percentage of participants | Placebo | Atacicept 150 mg With Loading Dose | Atacicept 150 mg Without Loading Dose | Adalimumab |
|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26 | 46.1 | 44.9 | 57.7 | 70.9 |
ACR50-CRP response is defined as \>=50% improvement from Baseline in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=50% improvement from Baseline in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).
| percentage of participants | Placebo | Atacicept 150 mg With Loading Dose | Atacicept 150 mg Without Loading Dose | Adalimumab |
|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 50 Response Based on CRP (ACR50-CRP) at Week 26 | 14.5 | 29.5 | 33.3 | 38.0 |
ACR70-CRP response is defined as \>=70% improvement from Baseline in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=70% improvement from Baseline in at least 3 of the following 5 measures: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function; and 5) acute-phase marker (CRP).
| percentage of participants | Placebo | Atacicept 150 mg With Loading Dose | Atacicept 150 mg Without Loading Dose | Adalimumab |
|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 70 Response Based on CRP (ACR70-CRP) at Week 26 | 5.3 | 12.8 | 12.8 | 17.7 |
The EULAR response criteria evaluate change in DAS28 scores represented as "good response", "moderate response", or "no response" considering both the current DAS28 score and the observed improvement from baseline. Participants were considered to have "good" or "moderate" EULAR response if at the time of assessment, their DAS28 score was less than or equal to (\<=) 5.1 and the improvement from baseline in their DAS28 score was greater than (\>) 0.6; or if at the time of assessment, their DAS28 score was \>5.1 and improvement from baseline in their DAS28 score was \>1.2.
| percentage of participants | Placebo | Atacicept 150 mg With Loading Dose | Atacicept 150 mg Without Loading Dose | Adalimumab |
|---|---|---|---|---|
| Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 26 | 59.2 | 64.1 | 67.9 | 81.0 |
An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.
| participants | Placebo | Atacicept 150 mg With Loading Dose | Atacicept 150 mg Without Loading Dose | Adalimumab |
|---|---|---|---|---|
| TEAEs | 38 | 49 | 49 | 50 |
| Serious TEAEs | 2 | 4 | 7 | 3 |
Collected over From the first dose of study drug up to 30 days after the last dose of study drug, assessed up to Week 38. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/76 (2.6%) | 23/76 (30.3%) |
| Atacicept 150 mg With Loading Dose | — | 4/78 (5.1%) | 27/78 (34.6%) |
| Atacicept 150 mg Without Loading Dose | — | 7/78 (9%) | 24/78 (30.8%) |
| Adalimumab | — | 3/79 (3.8%) | 22/79 (27.8%) |
| Event | Placebo | Atacicept 150 mg With Loading Dose | Atacicept 150 mg Without Loading Dose | Adalimumab |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/76 | 0/78 | 0/78 | 2/79 |
| CellulitisInfections and infestations | 1/76 | 0/78 | 0/78 | 0/79 |
| PericarditisCardiac disorders | 1/76 | 0/78 | 0/78 | 0/79 |
| Tendon ruptureInjury, poisoning and procedural complications | 1/76 | 0/78 | 0/78 | 0/79 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/76 | 0/78 | 1/78 | 0/79 |
| Laryngeal oedemaRespiratory, thoracic and mediastinal disorders | 0/76 | 1/78 | 0/78 | 0/79 |
| Obstructive airways disorderRespiratory, thoracic and mediastinal disorders | 0/76 | 0/78 | 1/78 | 0/79 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/76 | 0/78 | 1/78 | 0/79 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 0/76 | 0/78 | 1/78 | 0/79 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/76 | 1/78 | 0/78 | 0/79 |
| Event | Placebo | Atacicept 150 mg With Loading Dose | Atacicept 150 mg Without Loading Dose | Adalimumab |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/76 | 2/78 | 4/78 | 5/79 |
| BronchitisInfections and infestations | 4/76 | 5/78 | 6/78 | 3/79 |
| Upper respiratory tract infectionInfections and infestations | 2/76 | 4/78 | 4/78 | 6/79 |
| SinusitisInfections and infestations | 0/76 | 5/78 | 1/78 | 0/79 |
| HypertensionVascular disorders | 4/76 | 3/78 | 2/78 | 1/79 |
| LeukopeniaBlood and lymphatic system disorders | 4/76 | 1/78 | 1/78 | 3/79 |
| PharyngitisInfections and infestations | 1/76 | 3/78 | 4/78 | 3/79 |
| HeadacheNervous system disorders | 3/76 | 4/78 | 4/78 | 2/79 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/76 | 3/78 | 4/78 | 2/79 |
| Urinary tract infectionInfections and infestations | 3/76 | 4/78 | 4/78 | 2/79 |
Intention-to-treat (ITT) population included all randomized participants who received at least 1 study treatment dose.
| Age, Continuous(years) | Placebo | Atacicept 150 mg With Loading Dose | Atacicept 150 mg Without Loading Dose | Adalimumab | Total |
|---|---|---|---|---|---|
| Mean | 54.0 ± 10.3 | 53.0 ± 11.3 | 53.3 ± 13.2 | 53.3 ± 11.5 | 53.4 ± 11.6 |
| Sex: Female, Male(Participants) | Placebo | Atacicept 150 mg With Loading Dose | Atacicept 150 mg Without Loading Dose | Adalimumab | Total |
|---|---|---|---|---|---|
| Female | 64 | 65 | 66 | 64 | 259 |
| Male | 12 | 13 | 12 | 15 | 52 |
The record gives a start of Sep 2007, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 6 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein